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ABSTRACT
Purpose The Finnish National Esophago- Gastric Cancer 
Cohort (FINEGO) was established to combine the available 
registry data with detailed patient information to form a 
comprehensive, retrospective, population- based research 
platform of surgically treated oesophageal and gastric 
cancer in Finland. This cohort profile describes the 2045 
surgically treated patients with oesophageal cancer 
included in the FINEGO cohort.
Participants Registry data were collected from 
the National Cancer, Patient, Education and Death 
Registries from 1 January 1987 to 31 December 
2016. All patients over 18 years of age, who had either 
curative surgery, palliative surgery or salvage surgery 
for primary cancer in the oesophagus are included in 
this study.
Findings to date 2045 patients had surgery for 
oesophageal cancer in the selected time period. 
67.2% were man, and the majority had only minor 
comorbidities. The proportions of adenocarcinomas and 
squamous cell carcinomas were 43.1% and 44.4%, 
respectively, and 12.5% had other or missing histology. 
Only about 23% of patients received neoadjuvant 
therapy. Oesophagectomy was the treatment of choice 
and most patients were treated at low- volume centres, 
but median annual hospital volume increased over 
time. Median overall survival was 23 months, 5- year 
survival for all patients in the cohort was 32.9% and 
cancer- specific survival was 36.5%.
Future plans Even though Finland only has a 
population of 5.5 million, surgery for oesophageal 
carcinoma has not been centralised and therefore 
previously reported results have mostly been small, 
single- centre cohorts. Because of FINEGO, we now 
have a population- based, unselected cohort of 
surgically treated patients, enabling research on 
national trends over time regarding oesophageal 
cancer, including patient characteristics, tumour 
histology, stage and neoadjuvant treatment, surgical 
techniques, hospital volumes and patient mortality. 
Data collection is ongoing, and the cohort will be 
expanded to include more detailed data from patient 
records and national biobanks.
INTRODUCTION
Oesophageal carcinoma is an aggressive 
disease with poor prognosis. According to 
the European Cancer Registry based study on 
survival and care of cancer patients-5 (EURO-
CARE-5) study, only about 10% of patients are 
alive 5 years after being diagnosed.1 Cancer 
stage strongly influences oesophageal cancer 
survival, and unfortunately, the majority of 
patients have local (30%) or distant (40%) 
metastases at the time of diagnosis. This 
markedly lowers the 5- year survival from 39% 
in patients with the localised disease to 5% in 
cases with distant metastasis.2 Worldwide, it 
is the 12th most common cancer in terms of 
incidence, and the 6th most common cause of 
cancer death.3 According to the WHO, about 
53 000 people are diagnosed with oesopha-
geal cancer in Europe every year 2018. The 
incidence of oesophageal cancer is increasing 
Strengths and limitations of this study
 ► The main strengths include the population- based 
design with complete and accurate ascertainment 
of all surgically treated patients with oesophageal 
cancer in Finland, mitigating selection bias.
 ► Complete follow- up is a strength.
 ► The sample size is large enough to enable multivari-
able analysis, and analyses in smaller subgroups of 
patients.
 ► Exclusion of non- surgically treated patients and 
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in men in Finland, while it is slightly decreasing in women 
(figure 1).4 Of the histological subtypes, the incidence 
of oesophageal adenocarcinomas is increasing,5 6 while 
squamous cell carcinomas (SCC) are decreasing.6
Radical surgery combined with neoadjuvant chemo(ra-
diotherapy) is the standard of care for locally advanced, 
resectable oesophageal carcinomas.7 Surgery for oesoph-
ageal cancer is a high- risk procedure with high morbidity8 
and mortality.9 In early cases where the tumour is limited 
to the mucosa with no sign of nodal involvement, endo-
scopic treatment with either endoscopic mucosal resec-
tion (EMR) or endoscopic submucosal dissection (ESD), 
is a safe and effective option with excellent long- term 
results.10 11
Several studies support centralisation, showing a clear 
survival benefit for patients who had surgery at high- 
volume centres12 13 and by high- volume surgeons.14 15 
Studies have shown minimally invasive oesophagectomy 
(MIO) to be a feasible surgical technique in treating 
oesophageal carcinoma,16 17 with equal oncological results 
as open oesophagectomy.18 19 The number of MIOs in 
Europe are rising, with less than 20% of all eosophagecto-
mies performed with the transthoracic minimally invasive 
approach in 2007, compared with almost 50% in 2014.20
The nationwide registries in Finland systematically 
collect data on diseases, including oesophageal cancer. 
However, these data are limited in detail and scattered 
over several databases limiting the usability in surgical 
research as such. The Finnish National Esophago- Gastric 
Cancer Cohort (FINEGO) was established to retrospec-
tively gather detailed clinical data on all surgically treated 
oesophageal and gastric cancers in Finland to create a 
nationwide population- based registry, combining registry 
data, patient records data, as well as biobanks, for future 
research purposes.20
There are several gaps of knowledge in the diagnosis 
and treatment of oesophageal cancer. For instance, the 
changing demographics of oesophageal cancer and the 
effects of oncological treatment and centralisation in 
surgical patients are not completely clear. Furthermore, 
the associations between anastomotic methods, surgical 
approach, treatment complications and short- term and 
long- term mortality, as well as cancer survivorship are 
unclear. Lastly, the large- scale histological assessment of 
oesophageal cancer should provide robust information 
on potential new predictive or prognostic histological 
markers.
In this cohort profile, we describe the patients with 
oesophageal cancer included in the FINEGO cohort.
COHORT DESCRIPTION
FINEGO is a population- based, nationwide, a retrospec-
tive cohort study of all surgically treated patients with 
oesophageal and gastric cancer in Finland since 1987 and 
onwards. The collaborative group comprises of senior 
consultant upper gastrointestinal or thoracic surgeons 
from all five academic centres, and one non- academic 
central hospital, conducting oesophageal and gastric 
cancer surgery in Finland. In addition, senior oesophago-
gastric pathologists, oncologists and biostatisticians are 
involved in the design and execution of the study.
All patients over 18 years of age, who had either curative 
surgery, palliative surgery or salvage surgery for primary 
cancer of epithelial origin in the oesophagus or stomach 
are included in the FINEGO cohort. Patients who were 
treated endoscopically, that is, with endoscopic mucosal 
resection or submucosal dissection with curative intent, 
are also included. This study presents the oesophageal 
cancer cases included in the cohort.
Complete information on the details of data collection, 
sample size calculation and data management plan have 
been described in the study protocol.20
Data sources
The registry data were collected from the national regis-
tries from 1 January 1987 to 31 December 2016. All 
healthcare units in Finland are mandated by law to enter 
data into these registries making them highly comprehen-
sive.21 Registry data were combined using the immutable 
11- digit personal identification number assigned to all 
residents in Finland. Age and sex were derived from the 
personal identity numbers containing this information 
(the first six digits is the date of birth, and the eighth digit 
is based on the sex of the person).
The Finnish Cancer Registry provided information 
on cancer, including date and type of cancer, topog-
raphy (location), morphology (histology) information, 
cancer stage in a written format (local, locally advanced, 
advanced), as well as crude information on cancer treat-
ment, including the use of surgical treatment, chemo-
therapy, radiotherapy and hormonal treatment (yes/no).
The Finnish Patient Registry provided information on 
the discharge dates, diagnosis codes and operation codes 
assigned for each patient during that admission, as well 
as the code of the healthcare unit where the admission 
took place. This data was used for defining cancer diag-
nosis, treatment (operation codes), comorbidity (diag-
nosis codes) and hospital volume data (operation and 
Figure 1 The number of incident oesophageal cancers and 
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healthcare provider codes). Comorbidities were defined 
using the well- validated Charlson Comorbidity Index 
(CCI) not including oesophageal cancer, by retrieving 
diagnoses before but excluding the index admission 
for surgery.22 The annual hospital volume was assessed 
by calculating the number of benign and malignant 
oesophagectomies during the year of surgery in the 
hospital the patient was operated in for each patient.
Statistics Finland provided data on the dates and causes 
of death, as well as the highest education obtained by the 
patients.
Patient identification
Diagnosis numbers were searched for in the Finnish 
Cancer Registry and the Finnish Patient Registry to iden-
tify patients with cancer of the oesophagus (150.0–150.9 
in the 8th and 9th version of the International Classifica-
tion of Diseases, ICD-8 and ICD-9, and C15 in the ICD-10) 
as well as those with unclear oesophageal tumours (230 
in the ICD-8, 235 in the ICD-9 and D37.1 and D37.7 the 
ICD-10). Surgical codes were then searched for in the 
Finnish Patient Registry to identify those undergoing 
surgical treatment (oesophagectomy or endoscopic 
mucosal surgery). Using both registries concurrently 
guarantees a very high probability of finding all existing 
cases.
Statistical analysis
Statistical analysis was done using SPSS V.21.0 (SPSS). 
Kaplan- Meier curves and the Life Table method were 
used for survival analysis. Survival was calculated from 
the date of surgery until death or the end of follow- up, 
whichever came first. Cancer- specific mortality refers to 
mortality related to oesophagogastric cancer, which was 
selected as the most appropriate to take into account 
the potential misclassification between oesophageal and 
gastric cancers.23
Patient and public involvement
Patients or public were not involved in the development 
of the research question and study design or conducting 
the present study.
FINDINGS TO DATE
Between 1 January 1987 and 31 December 2016, 2045 
patients were surgically treated for oesophageal cancer in 
Finland (figure 2), which is higher than the initial esti-
mate of 1800 patients.20 According to the official statistics 
by the Finnish Cancer Registry, a total of 7280 patients 
were diagnosed with oesophageal cancer 1987–2016, 
and the number of incident oesophageal cancer cases 
and cancer deaths decreased during the study period 
(figure 1).4 The patients in FINEGO were mostly identi-
fied in both of the registries, but a small number (6.3%) 
were missing from the Cancer Registry (table 1).
At the time of surgery, the vast majority (86.1%) of 
patients were between 50 and 80 years of age. The median 
age of the patients remained quite constant over time, 
with a median of 65.5 years, ranging from 61 to 71 years. 
In the cohort, 67.2% (n=1375) of the patients were man. 
Some 65.4% (n=1337) had a CCI of 0, 22.8% (n=467) had 
CCI of 1 and 11.8% (n=241) had a CCI of 2 or higher 
(table 2). Educational data were missing for the majority 
of patients (59.9%, n=1225), but of those with data avail-
able 59.8% (n=491) had less than 12 years of education, 
while 28.8% (n=236) had an undergraduate degree and 
only 93 patients (11.3%) had more than 15 years of educa-
tion indicative of a graduate degree (table 2).
A slightly larger proportion of patients had SCC (44.4%, 
n=908) compared with adenocarcinomas (43.1%, n=882). 
The tumour was classified as ‘other’ in 6.3% (n=129) of 
the cases and in 6.2% (n=126) histological data were 
missing. The cancer was staged as local at the time of 
surgery in 28.9% (n=590) of the patients. In 18.7% (382) 
of the patients the cancer was staged as locally advanced, 
and in 18.7% (n=382) as advanced. In one- third of the 
cases, stage was either unclear or missing. Patient demo-
graphics are shown in table 2.
According to the information available in the Finnish 
Cancer Registry, the vast majority of surgically treated 
patients (77.3%, n=1581) did not receive neoadjuvant 
therapy. Neoadjuvant chemotherapy was administered to 
242 (11.8%) patients, while 222 patients received either 
chemoradiation (n=119, 5.8%) or radiotherapy alone 
Figure 2 Number of surgically treated patients with 
oesophageal cancer between 1987 and 2016.
Table 1 Identification of the patients with oesophageal 




Cancer diagnosis in both hospital 
discharge registry and cancer registry
1900 (92.9)
Cancer diagnosis in only hospital 
discharge registry
129 (6.3)
Cancer diagnosis in only cancer registry 14 (0.7)
Unclear tumour diagnosis and surgery 
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(n=103, 5%). The use of neoadjuvant therapy increased, 
as only 14.8% received neoadjuvant therapy during 1987–
2006, while 37.6% of the patients received it during 2007–
2016. Of all surgically treated patients, 84.7% (n=1733) 
had open surgery, whereas 12.4% (n=253) were operated 
with a minimally invasive approach. Oesophagectomy was 
by far the most common procedure (n=1767, 86.4%), 
followed by gastrectomy (n=191, 9.3%) and oesophago-
gastrectomy (n=28, 1.4%). In total, 59 patients in the 
cohort (2.9%) were treated with either EMR or ESD 
(table 3).
Median annual hospital volumes for oesophageal 
cancer surgery, on the other hand, did systematically and 
markedly increase over time. Between 1987 and 1999 the 
median annual hospital volume was 6 patients, from year 
2000 to 2009 the median was 10.5 patients and in the years 
2010–2016 the median had increased to 18 patients. Of 
all patients, 26.2% were treated in hospitals that perform 
1–5 operations per year, 37.5% in hospitals with an annual 
volume of 6–20 cases and 22.9% in hospitals that perform 
over 20 surgeries per year (table 3). Of the 671 patients 
undergoing oesophagectomy during the last 10 years of 
the study period (2007–2016), only 108 (16.1%) were 
treated in hospitals performing 1–5 oesophagectomies 
per year, while 282 (42.0) were treated in hospitals with 
6–20 oesophagectomies and 281 (41.9%) were treated 
in hospitals with >20 oesophagectomies. Median annual 
hospital volumes and median patient age over time are 
shown in figure 3.
Median overall survival (OS) was 23 months. 1- year, 
3- year, 5- year and 10- year OS for all patients in the 
cohort were 65.1%, 40.7%, 32.9% and 23.2%, respec-
tively. At the time of follow- up, 746 patients (36.5%) 
surgically treated for oesophageal carcinoma were still 
alive. All- cause mortality was 73.6% (n=1506), of which 
1299 (63.5%) were oesophagogastric cancer- related 
according to the causes of death registry. All- cause 
Table 2 Demographics of the surgically treated patients 




  ≤50 years 178 (8.7)
  51–60 years 449 (22)
  61–70 years 750 (36.7)
  71–80 years 561 (27.4)
  >80 years 107 (5.2)
Sex
  Male 1375 (67.2)
  Female 670 (32.8)
Education
  ≤12 years 491 (24.0)
  13–15 years 236 (11.5)
  >15 years 93 (4.5)
  Missing 1225 (59.9)
Charlson comorbidity index
  0 1337 (65.4)
  1 467 (22.8)
  2 161 (7.9)
  3 58 (2.8)
  ≥4 22 (1.1)
Stage
  Local 590 (28.9)
  Locally advanced 382 (18.7)
  Advanced 382 (18.7)
  Unclear 565 (27.6)
  Missing 126 (6.2)
Histology
  Adenocarcinoma 882 (43.1)
  Squamous cell 
carcinoma
908 (44.4)
  Other 129 (6.3)
  Missing 126 (6.2)
Table 3 Treatment details of the patients with oesophageal 




  Gastrectomy 191 (9.3)
  Oesophagectomy 1767 (86.4)
  Oesophagogastrectomy 28 (1.4)
  EMR or ESD 59 (2.9)
Surgical approach
  Open 1733 (84.7)
  Minimally invasive 253 (12.4)
  Not applicable 59 (2.9)
Neoadjuvant treatment
  None 1581 (77.3)
  Chemotherapy 242 (11.8)
  Radiotherapy 103 (5.0)
  Chemoradiotherapy 119 (5.8)
Hospital volume of oesophagectomy
  1–5 per year 535 (26.2)
  6–20 per year 766 (37.5)
  Over 20 per year 469 (22.9)
  Not applicable 275 (13.4)
EMR, endoscopic mucosal resection; ESD, endoscopic 
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and oesophagogastric cancer- specific mortality are 
depicted in figures 4 and 5.
STRENGTHS AND LIMITATIONS
FINEGO was established to combine the available registry 
data with detailed patient information to form a compre-
hensive, retrospective, population- based research plat-
form of surgically treated oesophageal and gastric cancer 
in Finland.20 This cohort profile describes the baseline 
registry data of the 2045 patients with oesophageal cancer 
included in the FINEGO cohort.
There are many strengths to the present study, the most 
important ones being the size of the cohort and the exten-
sive elimination of biases. With a total of 2045 patients, 
the sample size is large enough to allow for survival and 
regression analyses even in smaller subgroups of patients. 
Due to the population- based design that includes all 
surgically treated patients with oesophageal cancer in 
Finland, selection bias is mitigated. The fact that the 
cohort was created using a combination of registry and 
patient records data reduces information bias.
Because FINEGO is a cohort comprising of real- 
life, unselected data on surgical patients, it is mark-
edly different from other, global collaboratives such as 
the Worldwide Esophageal Cancer Collaboration24 or 
Esophagectomy Complications Consensus Group.25 These 
collaboratives typically only include expert, high- volume 
centres, whereas FINEGO allows for more wide- ranging 
conclusions and applications. The main limitations of the 
present study are its retrospective nature and the exclu-
sion of all non- surgical patients. The retrospective study 
design potentially weakens the data quality and generates 
a possibility of missing data on for example postopera-
tive complications, but on the other hand, it enables the 
quick establishment of a large patient cohort. To offset 
these potential issues, two separate high- quality databases 
were used. In addition, patient records are being manu-
ally collected and will be vigorously checked and vali-
dated for quality, further improving the reliability of the 
resulting cohort. The exclusion of non- surgical patients 
limits the potential of the cohort, as it excludes patients 
undergoing curatively intended or palliative chemo-
therapy and/or radiotherapy, reducing the possibilities 
to compare for example surgery and curatively intended 
chemoradiotherapy.
Some variables are not recorded in the registries and 
cannot be reliably retrieved from the patient records. 
However, the data quality and missing data will be metic-
ulously checked before running the substudies, and the 
missing data will be taken into account by using multiple 
imputation methods in the analyses to reduce bias from 
missing data. Even with thorough reviewing, this cohort 
will not be able to provide reliable data for studying 
potential risk factors for oesophageal carcinoma such as 
alcohol and tobacco use, dietary factors, exercise habits 
Figure 4 Kaplan- Meier curve depicting 10- year all- cause 
mortality in the surgically treated patients with oesophageal 
cancer.
Figure 5 Kaplan- Meier curve depicting 10- year 
oesophagogastric cancer- specific mortality in patients with 
oesophageal cancer.Figure 3 The median age at surgery and median annual 
hospital volume of oesophagectomies over time.
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and patient lifestyle or socioeconomic factors, as these 
are not reliably recorded in the records. Also, educational 
status is incomplete, with information on years of educa-
tion available for only 40.1% of patients, and it is not 
available in the patient records. Years of education do not 
necessarily translate into a certain socioeconomic stan-
dard further limiting its usefulness in describing patients. 
Other primarily missing or potentially unreliable infor-
mation, such as tumour stage at the time of operation 
or administered (neo)adjuvant therapy, are compre-
hensively recorded and can be found by manual review 
of patient records making these factors more useful 
and interesting for further substudies. Taken together, 
the FINEGO cohort will be most suitable for studying 
the effects of various surgical, oncological, pathological 
and surgeon- related and hospital- related factors in the 
surgical treatment of oesophageal cancer, while its value 
in evaluating risk factors of oesophageal cancer is limited.
A previous population- based study reported prognostic 
factors and survival in oesophageal cancer in a similar 
cohort in Sweden.26 The age distribution in the Swedish 
study was similar to the present study. In Finland, the 
median age of the patients did not increase over time 
despite the rise in life expectancy,27 but remained quite 
constant with a median of 65.5 years. The FINEGO cohort 
had a larger proportion of women, 32.8% compared with 
23.6%. There was a marked difference in gender distribu-
tion between patients with adenocarcinoma and patients 
with SCC in the Swedish cohort, and woman was a positive 
prognostic factor for survival in SCC.26 This interesting 
finding will be evaluated in future studies of the FINEGO 
cohort. The proportion of patients with comorbidities in 
this study was similar to the Swedish study.
In the present study, one- third of the patients’ stage was 
classified as ‘unclear’ or ‘missing’. Of all tumours, 28.9% 
were ‘local’, 18.7% ‘locally advanced’ and up to 18.7% 
were classified as ‘advanced’. These stages differ mark-
edly from several landmark studies, for example, in the 
ChemoRadiotherapy for Oesophageal cancer followed by 
Surgery Study (CROSS) trial 84% of the cases were clas-
sified as T3,28 and Low et al29 reported 66.6% T3 tumours 
when benchmarking surgical complications. Almost 
one- fifth of the patients having advanced disease raises 
concerns in the cancer registry variable reflecting tumour 
stage in the preoperative situation. A possible explana-
tion is that tumour stage might have not been reported 
to the cancer registry preoperatively due to unclear stage, 
only to be reported several months or years after the 
initial diagnosis, that is, at the time of distant recurrence. 
Reflecting the distribution of tumour stage in the previous 
studies, those having unclear or missing tumour stage are 
most likely to have locally advanced disease. To assess this, 
the Tumor- Node- Metastasis (TNM) stages in the FINEGO 
cohort will be validated manually from patient records 
against the registry data. Furthermore, the large number 
of unclear stages make staging data potentially unreliable. 
On the other hand, a large proportion of local tumours 
could explain the relatively good OS.
Neoadjuvant treatment was implemented in Finland 
around the year 2000, and it became standard care 
about a decade later. This is reflected in the results, and 
contributes to why only about 10% of the cohort, of which 
44% were SCC, received (chemo)radiotherapy which is 
considered standard- of- care today. However, during the 
last 10 years, more than one- third of the patients received 
neoadjuvant therapy. Potentially, there might be a lack of 
reporting of neoadjuvant treatment to the Finnish Cancer 
Registry by the clinicians when the initial cancer registry 
information has been already submitted at the time of 
diagnosis and when the decision to give neoadjuvant 
treatment has not yet been made. Neoadjuvant treatment 
will be validated from the patient files in future studies, as 
‘neoadjuvant’ was defined as chemotherapy, radiotherapy 
or chemoradiotherapy with a curative intent within 4 
months of diagnosis without specifics. Effect of neoadju-
vant therapy on survival will be one branch for further 
study, as we should be able to see a change in survival 
over time considering that very few received preoperative 
treatment before the year 2000.
Even though Finland only has a population of 
5.5 million, surgery for oesophageal carcinoma has not 
been centralised and most centres would be classified as 
low volume. Historically, this is due to the traditions and 
long geographical distances between hospitals. Median 
annual hospital volumes for oesophageal cancer surgery 
increased markedly during the study period. In the 1980s 
and 1990s, on average, only six patients had surgery at 
any given hospital each year. This number increased over 
time, and in the years 2010–2016 the median annual 
volume had tripled to 18 patients. This increase reflects 
governmental centralisation efforts. In the total cohort, 
only about 23% of the patients were treated in centres 
that perform over 20 operations annually, while a quarter 
of all patients (26.2%) were treated in hospitals with a 
very low annual volume of 1–5 operations.
According to the Finnish National Cancer Registry, 
372 patients were diagnosed with oesophageal cancer in 
2017, and 282 died of the disease.4 Five- year survival was 
17.3% disregarding stage and treatment.4 In the FINEGO 
cohort, 5- year survival of the surgically treated patients 
was 32.9%, which is markedly higher than in the unse-
lected Cancer Registry cohort.
Because of FINEGO, we now have a population- based, 
unselected cohort of surgically treated patients, enabling 
research on national trends over time regarding oesoph-
ageal cancer, including patient characteristics, tumour 
histology, stage and neoadjuvant treatment, surgical tech-
niques, hospital volumes and patient mortality. In the 
future, the study will be expanded every 5 years ensure 
that the most recent, accessible data is available for anal-
ysis. The nationwide collection of patient records and 
the collection of histological pre- operative gastroscopy 
and surgical specimen samples from national Biobanks is 
progressing. Once more data is gathered, several options 
for future research become available. Examples include 
assessment of the relevance of modifiable risk factors, 
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such as preoperative feeding, surgical approach or type 
of analgesia, optimal treatment and patient prognosis, 
and the association between hospital volume and surgical 
outcomes.
In conclusion, the FINEGO collaboration will continue 
to collect data, creating a solid platform for future 
research efforts into oesophageal and gastric cancers.
COLLABORATION
All data from FINEGO presented in this article are stored 
by the research group on safe servers at University of 
Oulu, Finland, and handled confidentially. Currently, 
only the research team has access to the data. Researchers 
interested in collaboration, for example joint efforts 
combining the dataset with other population- based 
studies, are welcome to contact Joonas Kauppila ( joonas. 
kauppila@ oulu. fi), principal investigator.
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